Innate PharmaIPHYF 29 EBIT per Share is $-0.63 as of Dec. 2025. GuruFocus rates IPHYF with a GF Score™ of 29/100 and a GF Value™ of $0.14 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,178 Biotechnology companies, Innate Pharma ranks worse than 94.23% on this metric.
Innate Pharma's EBIT per Share for the
six
months ended in Dec. 2025 was $-0.35.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.63.
During the past 3 years, the average EBIT per Share Growth Rate was -42.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Innate Pharma's EBIT per Share or its related term are showing as below:
IPHYF'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -44.6 Med: -9.4 Max: 46.8
Current: -42.5
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Innate Pharma was 46.80% per year. The lowest was -44.60% per year. And the median was -9.40% per year.
IPHYF's 3-Year EBIT Growth Rate is ranked worse than 94.23% of 1178
companies
in the Biotechnology industry
Industry Median: 15.55
vs IPHYF: -42.50
Innate Pharma's EBIT for the
six
months ended in Dec. 2025 was $-32.34 Mil.
Innate Pharma (OTCPK:IPHYF) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Innate Pharma EBIT per Share Related Terms
Innate Pharma EBIT per Share Historical Data
* Premium members only.
The historical data trend for Innate Pharma's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.63
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Innate Pharma (IPHYF) has a EBIT per Share of $-0.63 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Innate Pharma and its competitors. According to the industry distribution chart, Innate Pharma ranks #1110 out of 1178 companies in the Biotechnology industry, placing it in the top 94.2%.
Is Innate Pharma's EBIT per Share too high?
Innate Pharma's current EBIT per Share is $-0.63. Based on the distribution chart, Innate Pharma ranks #1110 out of 1178 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Innate Pharma has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Innate Pharma's EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Innate Pharma ranks #1110 out of 1178 companies for EBIT per Share. This places Innate Pharma in the lower half of its industry. The industry median EBIT per Share is 15.55. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.55, based on 1,178 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Innate Pharma and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Innate Pharma's current EBIT per Share is $-0.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innate Pharma stock overvalued right now?
Based on GuruFocus' analysis, Innate Pharma (IPHYF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.14, compared to a current price of $1.65 — trading 1078.6% above its estimated fair value. The current EBIT per Share is $-0.63. Innate Pharma's overall GF Score™ is 29/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Innate Pharma (IPHYF), the current EBIT per Share is $-0.63 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Innate Pharma (IPHYF) Overvalued in 2026?
Based on GuruFocus' analysis, Innate Pharma stock appears to be overvalued.
The current stock price of $1.65 is trading 1078.6% above its estimated GF Value™ of $0.14.
GuruFocus considers Innate Pharma to be Significantly Overvalued.
Key valuation signals for IPHYF:
EBIT per Share: $-0.63
GF Value™: $0.14 vs. price of $1.65 (1078.6% above fair value)
No single metric tells the full story. See the IPHYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.
29GF Score
Get the complete analysis for IPHYF
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IPHYF has been successfully added to your 
